Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining

Journal of Obstetrics and Gynaecology Research

Volumn 31, Issue 3, 2005, Pages 268-276

  Kritpracha, Krittaya ^a   Hanprasertpong, Jitti ^a,b   Chandeying, Verapol ^a   Dechsukhum, Chawaboon ^a   Geater, Alan ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

MIB 1 antibody; Ovarian carcinoma; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; KI 67 ANTIGEN; PARAFFIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PROGNOSIS; RETROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CARCINOMA, ENDOMETRIOID; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THAILAND;

EID: 21744439937     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2005.00270.x     Document Type: Article

References (27)

1. Heinz A, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. Annual report on the results of treatment in gynecologic cancer. J Epidemiol Biostat 2001; 6: 107-138.
2. Gynecologic Tumor Registry Annual Report 2001. Songkhla: Faculty of Medicine, Songklanagarind Hospital, 2004.
3. Berek JS. Ovarian cancer. In: Berek JS, Rinehart RD, Hillard PA, Adashi EY (eds). Novak's Textbook of Gynecology, 13th edn. Baltimore: William and Wilkins, 2002; 1245-1319.
4. Kerns BJ, Jordan PA, Faerman LL, Berchuck A, Bast RC, Layfield LJ. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1994; 101: 192-197.
5. Yaziji H, Gown AM. Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol 2001; 24: 64-78.
6. Garzetti GG, Ciavattini A, Goteri G et al. Ki-67 antigen immunostaining (MIB-1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 1995; 56: 169-174.
7. Al Kushi A, Lim P, Aquino-Parsons C, Gilks CB. Markers-of proliferative activity are predictors of patient outcome for low-grade endometriod adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 2002; 15: 365-371.
8. Dalquen P, Baschiera B, Chaffard R et al. MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smears. Acta Cytol 1997; 41: 229-237.
9. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Nictolis M, Biagini G. MIB-1 immunostaining in cervical carcinoma of young patients. Gynecol Oncol 1997; 67: 184-187.
10. Huuhtanen RL, Blomqvist CP, Wiklund TA et al. Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft tissue sarcoma. Br J Cancer 1999; 79: 945-951.
11. Borre M, Bentzen SM, Nerstrom B, Overgaard J. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 1998; 159: 1609-1614.
12. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumor characteristics in breast-cancer prognosis. Int J Cancer 1996; 69: 135-141.
13. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715.
14. Gerdes J, Li L, Schlueter. C et al. Immunobiochemistry and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138: 867-873.
15. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-322.
16. Key G, Kubbutat MH, Gerdes J. Assessment of the cell proliferation by means of an enzyme-linked immunosorbent assay based on the detection of the Ki-67 protein. J Immunol Methods 1994; 177: 113-117.
17. Key G, Becker MH, Duchrow M, Schluter C, Gerdes J. New Ki-67 equivalent murine monoclonal antibody (MIB1-3) prepared against recombinant parts of the Ki-67 antigen. Anal Cell Pathol 1992; 4: 181.
18. Harlozinska A, Bar JK, Sedlaczek P, Gerber J. Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology. Am J Clin Pathol 1996; 105: 334-340.
19. Anttila M, Kosma VM, Ji L et al. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol 1998; 16: 2591-2600.
20. Goff BA, Ries JA, Els LP, Coltrera MD, Gown AM. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol 1998; 70: 378-385.
21. Korkolopoulou P, Vassilopoulos I, Konstantinidou AE et al. The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 2002; 85: 404-414.
22. WHO. Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization, 1979; 48.
23. Kuwashima Y, Uehara T, Kurosumi M, Shiromizu K, Matsuzawa M, Kishi K. Cell dynamics of undifferentiated carcinomas of the ovary. Immunohistochemical estimation of their growth fraction and apoptotic status. Eur J Gynaecol Oncol 1995; 16: 268-273.
24. Brinkhuis M, Meijer GA, Baak JP. An evaluation of prognostic factors in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1995; 63: 115-124.
25. Omura GA, Brady MF, Homesley HD et al. Long-term follow-up and prognostic analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-1150.
26. Layfield LJ, Saria EA, Berchuck A et al. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. J Surg Oncol 1997; 66: 230-236.
27. Marx D, Meden H, Brune T et al. MIB-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res 1997; 17: 775-780.